Pfizer’s partner BioNTech boosted the 2021 delivery target for their COVID-19 vaccine to 2 billion doses, up from 1.3 billion previously, as they bring new production lines on stream and as more doses can be extracted per vial.
Special syringes known as low dead space syringes were instrumental in the increase, which would result in 1 billion people getting the designated two-dose regimen, BioNTech said in a presentation posted on Monday.
The syringes allow the extraction of six doses from a standard vial, instead of the usual five, by avoiding unused liquid left in a syringe.
“We now believe that we can potentially deliver approximately 2 billion doses in total by the end of 2021, which incorporates the updated six-dose label,” BioNTech said.
A new site in Marburg, Germany, acquired from Novartis in September, would boost annual capacity by up to 750 million doses when it becomes operational by end-February, it added.
Additional capacity by contractors, who supply ingredients and fill the finished substance into vials, had also helped to lift the target.
The Biotech firm added on its slides that 32.9 million doses had been shipped as per Sunday.
A spokeswoman said that 50 million doses had been produced at the end of 2020, as previously planned, but that deliveries had been held until specific orders are placed to avoid excess storage time.
Coronavirus: Indonesia approves China’s Sinovac vaccine amid COVID-19 surgeIndonesia gave Sinovac Biotech’s COVID-19 vaccine its first emergency use approval ... Coronavirus
Fake vaccines for COVID-19 selling for $1,000 on dark web: ExpertsWith critical COVID-19 vaccines in short supply, a black market for fake vaccines ... Coronavirus
Coronavirus: Russia says 1.5 mln people received Sputnik vaccine worldwideRussia announced Monday that 1.5 million people around the world had received its ... Coronavirus
EU doubles coronavirus vaccine deal with Pfizer-BioNTech to 600 mln dosesThe European Union reached a deal with Pfizer and BioNTech for 300 million ... Coronavirus